Diagnostic implications of MOG/AQP4 antibodies in recurrent optic neuritis
The present study aimed to detect myelin oligodendrocyte glycoprotein (MOG) and aquaporin-4 (AQP4) antibodies in serum specimens of patients with recurrent optic neuritis (RON) through establishing 293 cells with stable expression of MOG and the complete genomic sequence as the substrate using a cel...
Gespeichert in:
Veröffentlicht in: | Experimental and therapeutic medicine 2018-08, Vol.16 (2), p.950-958 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 958 |
---|---|
container_issue | 2 |
container_start_page | 950 |
container_title | Experimental and therapeutic medicine |
container_volume | 16 |
creator | Peng, Ying Liu, Lei Zheng, Yuanchu Qiao, Zhixin Feng, Kai Wang, Jiawei |
description | The present study aimed to detect myelin oligodendrocyte glycoprotein (MOG) and aquaporin-4 (AQP4) antibodies in serum specimens of patients with recurrent optic neuritis (RON) through establishing 293 cells with stable expression of MOG and the complete genomic sequence as the substrate using a cell-based assay (CBA). Furthermore, the clinical features of MOG antibody-positive recurrent optic neuritis (MOG-RON) were assessed. A total of 43 RON patients admitted to Beijing Tongren Hospital from December 2014 to May 2015 were enrolled, including 11 males and 32 females. The serum was collected from all patients, and the MOG and AQP4 antibodies were detected via the CBA. According to the results, the 43 patients were divided into four groups, namely the MOG antibody-positive group (n=11), the AQP4 antibody-positive group (n=20), the MOG/AQP4 antibody-positive group (n=1) and the MOG/AQP4 antibody-negative group (n=11). Clinical data were collected and all patients were followed up for 6 months, with parameters observed including the visual acuity, visual field and ocular fundus. The differences in the demographics, clinical features, characteristics of imaging examination, vision at onset and visual function recovery at 6 months after treatment were compared among the different groups. The characteristics of MOG antibody-positive RON were summarized. Of the 43 RON patients, 2.33% was both MOG and AQP4 antibody-positive, 27.91% were MOG antibody-positive. Compared with the AQP4-RON patients, there were relatively less MOG-RON patients (63.6 vs. 95.0%) and the canal segment and intracranial segment of the optic canal were less involved (P |
doi_str_mv | 10.3892/etm.2018.6273 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6090434</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A552969861</galeid><sourcerecordid>A552969861</sourcerecordid><originalsourceid>FETCH-LOGICAL-c548t-9f179c228e781ef64401ad4170fd2e54be59e2d28d5adaa38897088a033b4e243</originalsourceid><addsrcrecordid>eNptkU1v1DAQhi1ERau2R64oEhcu2fozGV-QVi1tqYoKEpwtrzNZXCX2YidI_HscdSm0wj54ZD_zemZeQl4zuhKg-RlO44pTBquGt-IFOWKt5jWjTL3cx1QDOySnOd_TslTDANQrcigoY5xKOCI3F95uQ8yTd5Ufd4N3dvIx5Cr21ae7q7P1l8-ysmHym9h5zJUPVUI3p4RhquJuSQs4Jz_5fEIOejtkPN2fx-Tb5Yev59f17d3Vx_P1be2UhKnWfanMcQ7YAsO-kZIy20nW0r7jqOQGlUbeceiU7awVALqlAJYKsZHIpTgm7x90d_NmxM6VSpIdzC750aZfJlpvnr4E_91s40_TUE2lWATe7QVS_DFjnszos8NhsAHjnA2nZbaglGoK-vYZeh_nFEp7hdJl6iBB_aW2dkDjQx_Lv24RNWuluG40NKxQq_9QZXc4ehcD9r7cP0moHxJcijkn7B97ZNQs_pviv1n8N4v_hX_z72Ae6T9ui9-3n6ln</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2096278485</pqid></control><display><type>article</type><title>Diagnostic implications of MOG/AQP4 antibodies in recurrent optic neuritis</title><source>PubMed Central</source><creator>Peng, Ying ; Liu, Lei ; Zheng, Yuanchu ; Qiao, Zhixin ; Feng, Kai ; Wang, Jiawei</creator><creatorcontrib>Peng, Ying ; Liu, Lei ; Zheng, Yuanchu ; Qiao, Zhixin ; Feng, Kai ; Wang, Jiawei</creatorcontrib><description>The present study aimed to detect myelin oligodendrocyte glycoprotein (MOG) and aquaporin-4 (AQP4) antibodies in serum specimens of patients with recurrent optic neuritis (RON) through establishing 293 cells with stable expression of MOG and the complete genomic sequence as the substrate using a cell-based assay (CBA). Furthermore, the clinical features of MOG antibody-positive recurrent optic neuritis (MOG-RON) were assessed. A total of 43 RON patients admitted to Beijing Tongren Hospital from December 2014 to May 2015 were enrolled, including 11 males and 32 females. The serum was collected from all patients, and the MOG and AQP4 antibodies were detected via the CBA. According to the results, the 43 patients were divided into four groups, namely the MOG antibody-positive group (n=11), the AQP4 antibody-positive group (n=20), the MOG/AQP4 antibody-positive group (n=1) and the MOG/AQP4 antibody-negative group (n=11). Clinical data were collected and all patients were followed up for 6 months, with parameters observed including the visual acuity, visual field and ocular fundus. The differences in the demographics, clinical features, characteristics of imaging examination, vision at onset and visual function recovery at 6 months after treatment were compared among the different groups. The characteristics of MOG antibody-positive RON were summarized. Of the 43 RON patients, 2.33% was both MOG and AQP4 antibody-positive, 27.91% were MOG antibody-positive. Compared with the AQP4-RON patients, there were relatively less MOG-RON patients (63.6 vs. 95.0%) and the canal segment and intracranial segment of the optic canal were less involved (P<0.05). The visual acuity at onset of MOG-RON was not inferior to that of AQP4-RON, and the visual recovery degree of MOG-RON was better (P<0.05). MOG antibody may be detected in the serum of certain RON patients, which have unique and different characteristics from AQP4 antibody-positive RON patients, so it may be used as a prognostic biomarker for RON. Furthermore, MOG antibody is present in the serum of patients with neuromyelitis optica spectrum disorders and may be a potential biomarker for these conditions.</description><identifier>ISSN: 1792-0981</identifier><identifier>EISSN: 1792-1015</identifier><identifier>DOI: 10.3892/etm.2018.6273</identifier><identifier>PMID: 30112048</identifier><language>eng</language><publisher>Greece: Spandidos Publications</publisher><subject>Age ; Alzheimer's disease ; Antibodies ; Aquaporins ; Diagnosis ; Edema ; Glycoproteins ; Hospitals ; Laboratories ; Males ; Medical diagnosis ; Metabolism ; Multiple sclerosis ; Nervous system ; NMR ; Nuclear magnetic resonance ; Optic nerve ; Optic neuritis ; Pain</subject><ispartof>Experimental and therapeutic medicine, 2018-08, Vol.16 (2), p.950-958</ispartof><rights>COPYRIGHT 2018 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2018</rights><rights>Copyright © 2018, Spandidos Publications 2018</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c548t-9f179c228e781ef64401ad4170fd2e54be59e2d28d5adaa38897088a033b4e243</citedby><cites>FETCH-LOGICAL-c548t-9f179c228e781ef64401ad4170fd2e54be59e2d28d5adaa38897088a033b4e243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090434/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090434/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30112048$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Peng, Ying</creatorcontrib><creatorcontrib>Liu, Lei</creatorcontrib><creatorcontrib>Zheng, Yuanchu</creatorcontrib><creatorcontrib>Qiao, Zhixin</creatorcontrib><creatorcontrib>Feng, Kai</creatorcontrib><creatorcontrib>Wang, Jiawei</creatorcontrib><title>Diagnostic implications of MOG/AQP4 antibodies in recurrent optic neuritis</title><title>Experimental and therapeutic medicine</title><addtitle>Exp Ther Med</addtitle><description>The present study aimed to detect myelin oligodendrocyte glycoprotein (MOG) and aquaporin-4 (AQP4) antibodies in serum specimens of patients with recurrent optic neuritis (RON) through establishing 293 cells with stable expression of MOG and the complete genomic sequence as the substrate using a cell-based assay (CBA). Furthermore, the clinical features of MOG antibody-positive recurrent optic neuritis (MOG-RON) were assessed. A total of 43 RON patients admitted to Beijing Tongren Hospital from December 2014 to May 2015 were enrolled, including 11 males and 32 females. The serum was collected from all patients, and the MOG and AQP4 antibodies were detected via the CBA. According to the results, the 43 patients were divided into four groups, namely the MOG antibody-positive group (n=11), the AQP4 antibody-positive group (n=20), the MOG/AQP4 antibody-positive group (n=1) and the MOG/AQP4 antibody-negative group (n=11). Clinical data were collected and all patients were followed up for 6 months, with parameters observed including the visual acuity, visual field and ocular fundus. The differences in the demographics, clinical features, characteristics of imaging examination, vision at onset and visual function recovery at 6 months after treatment were compared among the different groups. The characteristics of MOG antibody-positive RON were summarized. Of the 43 RON patients, 2.33% was both MOG and AQP4 antibody-positive, 27.91% were MOG antibody-positive. Compared with the AQP4-RON patients, there were relatively less MOG-RON patients (63.6 vs. 95.0%) and the canal segment and intracranial segment of the optic canal were less involved (P<0.05). The visual acuity at onset of MOG-RON was not inferior to that of AQP4-RON, and the visual recovery degree of MOG-RON was better (P<0.05). MOG antibody may be detected in the serum of certain RON patients, which have unique and different characteristics from AQP4 antibody-positive RON patients, so it may be used as a prognostic biomarker for RON. Furthermore, MOG antibody is present in the serum of patients with neuromyelitis optica spectrum disorders and may be a potential biomarker for these conditions.</description><subject>Age</subject><subject>Alzheimer's disease</subject><subject>Antibodies</subject><subject>Aquaporins</subject><subject>Diagnosis</subject><subject>Edema</subject><subject>Glycoproteins</subject><subject>Hospitals</subject><subject>Laboratories</subject><subject>Males</subject><subject>Medical diagnosis</subject><subject>Metabolism</subject><subject>Multiple sclerosis</subject><subject>Nervous system</subject><subject>NMR</subject><subject>Nuclear magnetic resonance</subject><subject>Optic nerve</subject><subject>Optic neuritis</subject><subject>Pain</subject><issn>1792-0981</issn><issn>1792-1015</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkU1v1DAQhi1ERau2R64oEhcu2fozGV-QVi1tqYoKEpwtrzNZXCX2YidI_HscdSm0wj54ZD_zemZeQl4zuhKg-RlO44pTBquGt-IFOWKt5jWjTL3cx1QDOySnOd_TslTDANQrcigoY5xKOCI3F95uQ8yTd5Ufd4N3dvIx5Cr21ae7q7P1l8-ysmHym9h5zJUPVUI3p4RhquJuSQs4Jz_5fEIOejtkPN2fx-Tb5Yev59f17d3Vx_P1be2UhKnWfanMcQ7YAsO-kZIy20nW0r7jqOQGlUbeceiU7awVALqlAJYKsZHIpTgm7x90d_NmxM6VSpIdzC750aZfJlpvnr4E_91s40_TUE2lWATe7QVS_DFjnszos8NhsAHjnA2nZbaglGoK-vYZeh_nFEp7hdJl6iBB_aW2dkDjQx_Lv24RNWuluG40NKxQq_9QZXc4ehcD9r7cP0moHxJcijkn7B97ZNQs_pviv1n8N4v_hX_z72Ae6T9ui9-3n6ln</recordid><startdate>20180801</startdate><enddate>20180801</enddate><creator>Peng, Ying</creator><creator>Liu, Lei</creator><creator>Zheng, Yuanchu</creator><creator>Qiao, Zhixin</creator><creator>Feng, Kai</creator><creator>Wang, Jiawei</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180801</creationdate><title>Diagnostic implications of MOG/AQP4 antibodies in recurrent optic neuritis</title><author>Peng, Ying ; Liu, Lei ; Zheng, Yuanchu ; Qiao, Zhixin ; Feng, Kai ; Wang, Jiawei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c548t-9f179c228e781ef64401ad4170fd2e54be59e2d28d5adaa38897088a033b4e243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Age</topic><topic>Alzheimer's disease</topic><topic>Antibodies</topic><topic>Aquaporins</topic><topic>Diagnosis</topic><topic>Edema</topic><topic>Glycoproteins</topic><topic>Hospitals</topic><topic>Laboratories</topic><topic>Males</topic><topic>Medical diagnosis</topic><topic>Metabolism</topic><topic>Multiple sclerosis</topic><topic>Nervous system</topic><topic>NMR</topic><topic>Nuclear magnetic resonance</topic><topic>Optic nerve</topic><topic>Optic neuritis</topic><topic>Pain</topic><toplevel>online_resources</toplevel><creatorcontrib>Peng, Ying</creatorcontrib><creatorcontrib>Liu, Lei</creatorcontrib><creatorcontrib>Zheng, Yuanchu</creatorcontrib><creatorcontrib>Qiao, Zhixin</creatorcontrib><creatorcontrib>Feng, Kai</creatorcontrib><creatorcontrib>Wang, Jiawei</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Experimental and therapeutic medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peng, Ying</au><au>Liu, Lei</au><au>Zheng, Yuanchu</au><au>Qiao, Zhixin</au><au>Feng, Kai</au><au>Wang, Jiawei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diagnostic implications of MOG/AQP4 antibodies in recurrent optic neuritis</atitle><jtitle>Experimental and therapeutic medicine</jtitle><addtitle>Exp Ther Med</addtitle><date>2018-08-01</date><risdate>2018</risdate><volume>16</volume><issue>2</issue><spage>950</spage><epage>958</epage><pages>950-958</pages><issn>1792-0981</issn><eissn>1792-1015</eissn><abstract>The present study aimed to detect myelin oligodendrocyte glycoprotein (MOG) and aquaporin-4 (AQP4) antibodies in serum specimens of patients with recurrent optic neuritis (RON) through establishing 293 cells with stable expression of MOG and the complete genomic sequence as the substrate using a cell-based assay (CBA). Furthermore, the clinical features of MOG antibody-positive recurrent optic neuritis (MOG-RON) were assessed. A total of 43 RON patients admitted to Beijing Tongren Hospital from December 2014 to May 2015 were enrolled, including 11 males and 32 females. The serum was collected from all patients, and the MOG and AQP4 antibodies were detected via the CBA. According to the results, the 43 patients were divided into four groups, namely the MOG antibody-positive group (n=11), the AQP4 antibody-positive group (n=20), the MOG/AQP4 antibody-positive group (n=1) and the MOG/AQP4 antibody-negative group (n=11). Clinical data were collected and all patients were followed up for 6 months, with parameters observed including the visual acuity, visual field and ocular fundus. The differences in the demographics, clinical features, characteristics of imaging examination, vision at onset and visual function recovery at 6 months after treatment were compared among the different groups. The characteristics of MOG antibody-positive RON were summarized. Of the 43 RON patients, 2.33% was both MOG and AQP4 antibody-positive, 27.91% were MOG antibody-positive. Compared with the AQP4-RON patients, there were relatively less MOG-RON patients (63.6 vs. 95.0%) and the canal segment and intracranial segment of the optic canal were less involved (P<0.05). The visual acuity at onset of MOG-RON was not inferior to that of AQP4-RON, and the visual recovery degree of MOG-RON was better (P<0.05). MOG antibody may be detected in the serum of certain RON patients, which have unique and different characteristics from AQP4 antibody-positive RON patients, so it may be used as a prognostic biomarker for RON. Furthermore, MOG antibody is present in the serum of patients with neuromyelitis optica spectrum disorders and may be a potential biomarker for these conditions.</abstract><cop>Greece</cop><pub>Spandidos Publications</pub><pmid>30112048</pmid><doi>10.3892/etm.2018.6273</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1792-0981 |
ispartof | Experimental and therapeutic medicine, 2018-08, Vol.16 (2), p.950-958 |
issn | 1792-0981 1792-1015 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6090434 |
source | PubMed Central |
subjects | Age Alzheimer's disease Antibodies Aquaporins Diagnosis Edema Glycoproteins Hospitals Laboratories Males Medical diagnosis Metabolism Multiple sclerosis Nervous system NMR Nuclear magnetic resonance Optic nerve Optic neuritis Pain |
title | Diagnostic implications of MOG/AQP4 antibodies in recurrent optic neuritis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T17%3A22%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diagnostic%20implications%20of%20MOG/AQP4%20antibodies%20in%20recurrent%20optic%20neuritis&rft.jtitle=Experimental%20and%20therapeutic%20medicine&rft.au=Peng,%20Ying&rft.date=2018-08-01&rft.volume=16&rft.issue=2&rft.spage=950&rft.epage=958&rft.pages=950-958&rft.issn=1792-0981&rft.eissn=1792-1015&rft_id=info:doi/10.3892/etm.2018.6273&rft_dat=%3Cgale_pubme%3EA552969861%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2096278485&rft_id=info:pmid/30112048&rft_galeid=A552969861&rfr_iscdi=true |